Request Demo

Last update 08 May 2025

Tuberculoma

Last update 08 May 2025

Basic Info

Synonyms

Tuberculoma, Tuberculoma (disorder), Tuberculoma, NOS

+ [6]

Introduction

A tumor-like mass resulting from the enlargement of a tuberculous lesion.

Drugs associated with Tuberculoma

Ethambutol Hydrochloride/Isoniazid

Target

rpoB

Mechanism

rpoB inhibitors

Active Org.-

Originator Org.-

Active Indication

Tuberculoma

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with Tuberculoma

IRCT20221108056446N6

/ SuspendedNot ApplicableIIT

A comparative study of CSF leak rate in Duraplasty using the Edge-In method with the conventional method in patients with spinal cord injury

Start Date20 Apr 2024

Sponsor / Collaborator

Isfahan University of Medical Sciences

CTRI/2019/05/019222

/ RecruitingPhase 1

A Comparative study comparing intensified treatment with Moxifloxacin/Pyrazinamide versus standard Anti-tubercular therapy for CNS Tuberculoma

Start Date27 May 2019

Sponsor / Collaborator-

ChiCTR-ONC-13003995

/ CompletedNot ApplicableIIT

Brain-CT position past uses in brain tumor surgery with tuberculosis

Start Date01 Dec 2013

Sponsor / Collaborator-

100 Clinical Results associated with Tuberculoma

100 Translational Medicine associated with Tuberculoma

0 Patents (Medical) associated with Tuberculoma

2,977

Literatures (Medical) associated with Tuberculoma

01 Dec 2025·Child's Nervous System

Central nervous system tuberculoma in children: tertiary hospital experience in Turkey in the last quarter century

Article

Author: Totik, Nazlı ; Çay, Ümmühan ; Çetin, Fatma Tuğba ; Kaya, Ömer ; Alabaz, Derya ; Gündeşlioğlu, Özlem Özgür ; Bakanoğlu, Emel ; Kaya, Bedir

INTRODUCTIONTuberculomas represent a significant complication of central nervous system (CNS) infection resulting from tuberculosis. The objective of our study was to evaluate the demographic and clinical characteristics, diagnosis, treatment, and prognosis of pediatric patients with CNS tuberculoma.METHODSThe study population comprised patients aged 0-18 years who were diagnosed with CNS tuberculoma in the Division of Pediatric Infectious Diseases at Cukurova University Balcali Hospital between January 1, 2002, and September 1, 2024. A retrospective analysis was conducted on the files to examine the demographic and clinical characteristics, radiological data, and treatment of the patients. The definitive diagnosis was established through acid-fast bacilli staining and tuberculosis culture of the CNS lesion. The probable diagnosis was made on the basis of clinical epidemiologic factors, histopathology, molecular methods, and typical radiographic findings.RESULTSCNS was tuberculoma detected in 22 patients (8.3%) of the 265 individuals diagnosed with TB. Of the total number of patients, 12 (54.5%) were male and 10 (45.5%) were female. The median age of the patients was 60 months (25th to 75th interquartile range 15.8 and 144.0, respectively), and the most common presenting complaint was fever (77.3%). A lumbar puncture was conducted in 19 patients (86.4%), and brain imaging was performed on all of them. Biopsies from the brain lesions were obtained in two patients. The mean follow-up period was 9.3 ± 5.4 years. The antituberculosis treatment was administered until the lesions had disappeared. Complete recovery was observed in 14 patients (63.6%), while eight patients (36.4%) exhibited sequelae. Tuberculoma did not result in mortalities among the patients.CONCLUSIONDiagnosis of CNS tuberculoma is often difficult due to non-specific symptoms and difficulties in sampling. Early diagnosis and appropriate treatment can prevent mortality and morbidity. When we encounter suspicious radiologic findings in brain imaging, especially magnetic resonance imaging, it should be considered in the differential diagnosis.

01 Jun 2025·Respiratory Medicine

Clinical predictive model for identifying high-risk factors in pleurisy tuberculoma patients

Article

Author: Dai, Guangchuan ; Hu, Weiyi ; Wang, Tianzhen ; Chen, Shanshan ; Chen, Cheng ; Guo, Yicheng ; Yang, Chen ; Yin, Chunyang ; Gao, Weiwei ; Zeng, Yi ; Tang, Xiaoli

INTRODUCTIONPleurisy tuberculoma (PTM) is a neoplastic lesion that primarily affects the pleural wall or internal organs. The majority of PTM cases are observed during the treatment of tuberculous pleural effusion(TPE), and although the precise pathogenesis remains unclear, there is a significant association between these two conditions. To identify high-risk factors for the development of PTM, we developed a clinical predictive model aimed at providing more insightful information for the development of PTM.METHODSA retrospective study was conducted on patients diagnosed with PTM or TPE who were treated at Nanjing Chest Hospital and the Second Hospital of Nanjing from March 2013 to April 2024. Predictors were identified using logistic regression, LASSO regression, and optimal subset regression. The performance of all models was evaluated using receiver operating characteristic (ROC) curves, calibration curves, decision curve analysis (DCA), and clinical impact curves to establish the final clinical predictive model. Internal and external validation was performed to assess the model's performance.RESULTSThe final predictive model included two key risk factors associated with the development of PTM: Ki-67⁺CD4⁺T cells and Ki-67⁺CD8⁺T cells. The final model demonstrated good clinical net benefit and predictive validity, high predictive accuracy (Brier score: 0.033, 95 %CI: 0.011-0.054), and strong differentiation (AUC: 0.987, 95 %CI: 0.969-1.000). The model's robust performance was demonstrated by both internal and external verification.CONCLUSIONSThe predictive model utilizing Ki-67+CD4+T cells and Ki-67+CD8+T cells can assist clinicians in making early predictions of PTM.

01 Jun 2025·Photodiagnosis and Photodynamic Therapy

Swept-source optical coherence tomography features of choroidal tumors and tumor mimics: A 5-year retrospective study

Article

Author: Wei, Wenbin ; Dong, Li ; Zhang, Ruiheng ; Zhou, Wenda ; Liu, Yueming ; Li, Yitong

BACKGROUNDThese lack a thorough comparison of swept-source optical coherence tomography (SS-OCT) features among different kinds of choroidal tumors and tumor mimics.METHODSThis retrospective case series study based on 305 eyes from 298 consecutive patients with choroidal tumors or tumor mimics treated at Beijing Tongren Hospital between July 2019 and March 2024. The diagnostic performance of SS-OCT features in distinguishing malignant tumors were evaluated.RESULTSThe present study included choroidal melanoma (n = 113), choroidal lymphoma (n = 11), choroidal metastasis (n = 9), choroidal hemangioma (n = 92), choroidal nevus (n = 9), choroidal osteoma (n = 32), RPE adenoma (n = 4), choroidal tuberculoma (n = 2), posterior scleritis (n = 2), and choroidal leiomyoma (n = 1). The median thickness and largest basal diameter were 2.9 mm (interquartile range: 2.0-4.2) and 9.0 mm (interquartile range: 5.7-11.3). Among all SS-OCT features, multivariable logistic regression showed optical shadowing (Odds Ratio [OR]=104.1, 95 %CI: 5.33-2028.8), subretinal fluid (<3 mm from margin: OR=100.9, 95 %CI: 2.21-4607; >3 mm from margin: OR=24.2, 95 %CI: 2.14-274.0), and overlying choriocapillaris complete loss (OR=52.3, 95 %CI: 4.85-552.7) highly indicated malignant choroidal tumor. Choriocapillaris loss was more sensitive (0.962, 95 %CI: 0.926-0.992) in identifying malignant tumors than optical shadowing (0.791, 95 %CI: 0.730-0.850) and subretinal fluid >3 mm from the tumor margin (0.714, 95 %CI: 0.639-0.788). Choriocapillaris loss also showed high sensitivity (0.923, 95 %CI: 0.919-1.000) and specificity (0.973, 95 %CI: 0.940-1.000) in identifying choroidal melanoma from choroidal nevus. The appearance of choriocapillaris loss or subretinal fluid >3 mm from the tumor margin showed 100 % sensitivity in identifying malignant amelanotic tumors.CONCLUSIONSChoriocapillaris loss, optical shadowing, and extensive subretinal fluid can be used to identify malignant tumors.

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Tuberculoma

Basic Info

Related

Analysis